Pro MedicusPMDIY +3.45%77 Return-on-Tangible-Asset is 83.18% as of Dec. 2025, which is 139% above its 10-year median of 34.75. GuruFocus rates PMDIY with a GF Score™ of 77/100 and a GF Value™ of $39.90 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 682 Healthcare Providers & Services companies, Pro Medicus ranks better than 99.27% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pro Medicus's annualizedNet Income for the quarter that ended in Dec. 2025 was $227.5 Mil. Pro Medicus's average total tangible assets for the quarter that ended in Dec. 2025 was $273.6 Mil. Therefore, Pro Medicus's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 83.18%.
The historical rank and industry rank for Pro Medicus's Return-on-Tangible-Asset or its related term are showing as below:
PMDIY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 18.42 Med: 34.75 Max: 63.84
Current: 63.84
During the past 13 years, Pro Medicus's highest Return-on-Tangible-Asset was 63.84%. The lowest was 18.42%. And the median was 34.75%.
PMDIY's Return-on-Tangible-Asset is ranked better than 99.27% of 682
companies
in the Healthcare Providers & Services industry
Industry Median: 2.465
vs PMDIY: 63.84
Pro Medicus (OTCPK:PMDIY) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Pro Medicus Return-on-Tangible-Asset Related Terms
Pro Medicus Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Pro Medicus's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMDIY vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Pro Medicus's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Pro Medicus's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 83.18% mean?
Pro Medicus (PMDIY) has a Return-on-Tangible-Asset of 83.18% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pro Medicus and its competitors. This is 139% above median its historical median of 34.75. Over the past decade, Pro Medicus' Return-on-Tangible-Asset has ranged from 18.42 to 63.84. According to the industry distribution chart, Pro Medicus ranks #5 out of 682 companies in the Healthcare Providers & Services industry, placing it in the top 0.7%.
Is Pro Medicus' Return-on-Tangible-Asset too high?
Pro Medicus' current Return-on-Tangible-Asset of 83.18% is 139% above median its 10-year median of 34.75. Over the past 10 years, this metric has ranged from a low of 18.42 to a high of 63.84. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.47. Pro Medicus' value of 83.18% is 3274.4% above this industry median. Based on the distribution chart, Pro Medicus ranks #5 out of 682 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pro Medicus has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #5 out of 682 companies for Return-on-Tangible-Asset. This places Pro Medicus in the top 1% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.47. Pro Medicus' value of 83.18% is 3274.4% above this benchmark. Historically, Pro Medicus' own Return-on-Tangible-Asset has ranged from 18.42 to 63.84 over the past decade. While the company's 10-year median is 34.75 vs. the industry median of 2.47, Pro Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.47, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current Return-on-Tangible-Asset of 83.18% is 3274.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pro Medicus and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current Return-on-Tangible-Asset is 83.18%, which is 139% above median its own 10-year median of 34.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (PMDIY) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.90, compared to a current price of $30.00 — trading 24.8% below its estimated fair value. The current Return-on-Tangible-Asset is 83.18%, which is 139% above median its 10-year median of 34.75 and 3274.4% above the Healthcare Providers & Services industry median of 2.47. Pro Medicus' overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Pro Medicus (PMDIY), the current Return-on-Tangible-Asset is 83.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (PMDIY) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of $30.00 is trading 24.8% below its estimated GF Value™ of $39.90.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for PMDIY:
Return-on-Tangible-Asset: 83.18% (139% above median its 10-year median of 34.75)
GF Value™: $39.90 vs. price of $30.00 (24.8% below fair value)
Industry Position: 3274.4% above the Healthcare Providers & Services median (#5 of 682)
No single metric tells the full story. See the PMDIY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
77GF Score
Get the complete analysis for PMDIY
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMDIY has been successfully added to your 
